STOCK TITAN

Emmaus expects roughly $400K Q3 2026 operating loss

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

Emmaus Life Sciences, Inc. (EMMA) said it cannot file its Form 10-Q for the quarter ended September 30, 2026, by the prescribed due date because it needs additional time to value the conversion feature of its outstanding convertible promissory notes. It anticipates filing by the fifth calendar day following the prescribed due date.

Emmaus estimates net revenues will decline more than 40% compared with 2025, primarily following completion of its U.S. out-license of Endari to NeoImmuneTech, Inc. during Q3 2026. Gross profit is expected to decline approximately 50%. The company estimates a loss from operations of approximately $0.4 million, compared with income from operations of approximately $0.7 million in the same period in 2025, and a net loss of approximately $0.06 per share, versus $0.03 per share in 2025. The final net loss depends on the completed valuation.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Q3 2026 net revenues expected to fall more than 40% versus 2025.
  • Major point. Forward-looking: it has not happened yet and may not happen.Operating result shifts from approximately $0.7 million income to a $0.4 million loss.
Net revenue decline More than 40% Estimated for the quarter ended September 30, 2026, compared with 2025.
Gross profit decline Approximately 50% Estimated compared with the same period in 2025.
Operating result Approximately $0.4 million loss Estimated for the quarter ended September 30, 2026, versus approximately $0.7 million income in the same period in 2025.
Net loss per share Approximately $0.06 per share Estimated for the quarter ended September 30, 2026, compared with a $0.03 per-share net loss in the same period in 2025.
conversion feature financial
"valuation of the conversion feature of our outstanding convertible promissory notes"
A conversion feature is a built-in option in a security—such as a bond or preferred share—that allows the holder to exchange it for a set number of common shares under specified conditions. It matters to investors because it mixes steady income or priority rights with potential upside if the stock rises, while also carrying the risk of diluting existing owners; think of it like a voucher that can be cashed in for stock when it becomes more valuable.
convertible promissory notes financial
"our outstanding convertible promissory notes"
A convertible promissory note is a loan a company takes that can later be turned into shares instead of being paid back in cash; think of lending money now in exchange for a voucher that can become ownership later. Investors care because it mixes credit risk and potential ownership upside—it can protect lenders if a company struggles while also diluting existing shareholders when converted, affecting future share value and investor returns.
out-license financial
"completion of our out-license of Endari in the U.S."
Out-license is when a company gives another firm the legal right to use, develop, manufacture or sell a technology, drug or product in exchange for payments such as upfront fees, milestone payments and ongoing royalties. For investors it matters because out-licensing can bring near-term cash, reduce development and commercialization risk, and provide a steady revenue stream—similar to renting a proven recipe to someone else so they handle the cooking and distribution while you collect fees.
gross profit financial
"a decline in gross profit of approximately 50%"
Gross profit is the amount a business keeps from sales after subtracting the direct costs to make or buy the products or services sold — like the money left from a lemonade stand after paying for lemons, sugar and cups. Investors watch gross profit to judge how well a company’s core operations and pricing cover those direct costs, revealing its basic profitability and whether margins are improving or shrinking over time.
loss from operations financial
"resulting in a loss from operations of approximately $0.4 million"
Loss from operations is the money a company loses from its main business activities, like selling products or services, before considering other expenses or income. It shows whether the company's core business is making or losing money. This figure matters because it helps investors understand if the business is running efficiently or struggling to earn enough to cover its costs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Q3 2026 results does EMMA expect?

Emmaus estimates net revenues for the quarter ended September 30, 2026, will decline more than 40% compared with 2025, and gross profit will decline approximately 50%. It estimates a loss from operations of approximately $0.4 million, versus income from operations of approximately $0.7 million in the same period in 2025.

Why is EMMA's Q3 2026 10-Q late?

Emmaus said it needs additional time to complete the valuation of the conversion feature of its outstanding convertible promissory notes. It anticipates filing the report on or before the fifth calendar day following the prescribed due date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

  SEC File Number: 001-35527
  CUSIP Number: 29137T101

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

(Check one):

 

☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN
☐ Form N-CSR

 

For Period Ended: September 30, 2026

 

☐ Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q

 

For the Transition Period Ended: _______________

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
 

 

PART I - REGISTRANT INFORMATION

 

Full Name of Registrant: Emmaus Life Sciences, Inc.
Former Name if Applicable:  
Address of Principal Executive Office (Street and Number): 21250 Hawthorne Boulevard, Suite 800
City, State and Zip Code: Torrance, California 90503

  

 

 

 

PART II - RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

☒ (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒ (b) The subject annual report, semi-annual report, transition report on Forms 10-K, 20-F, 11-K, Form N-CEN, or Form N-CSR or portion thereof, will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

  

PART III - NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period.

 

Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) is unable to file, without unreasonable effort or expense, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Form 10-Q”) by the prescribed due date. We will require additional time to complete the valuation of the conversion feature of our outstanding convertible promissory notes and anticipate filing the Form 10-Q on or before the fifth calendar day following the prescribed due date.

 

PART IV - OTHER INFORMATION

 

  (1) Name and telephone number of the person to contact in regard to this notification: 

 

Willis Lee   (310) 214-0065
(Name)   (Area Code) (Telephone number)

 

  (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed? If answer is no, identify report(s): 

 

☒ Yes ☐ No

  (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof: 

 

☒ Yes ☐ No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

  

 

 

  

 

Emmaus Life Sciences, Inc.
(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: November 16, 2026 /s/ Willis Lee
  Willis Lee
Chairman and Chief Executive Officer

 

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

 

 PART IV - OTHER INFORMATION

 

(3) We estimate that net revenues for the quarter ended September 30, 2026, will reflect a decline of more than 40%, as compared to 2025 due primarily to the completion of our out-license of Endari in the U.S. to NeoImmuneTech, Inc. during the Q3 2026. We expect the decline in net revenues to result in a decline in gross profit of approximately 50%, partially offset by a reduction in operating expenses as compared to the same period in 2025, resulting in a loss from operations of approximately $0.4 million for the quarter ended September 30, 2026, as compared to income from operations of approximately $0.7 million in 2025. Based on currently available information, we estimate that we incurred a net loss of approximately $0.06 per share in the quarter ended September 30, 2026, as compared to a net loss of $0.03 per share in the same period in 2025. The actual net loss will depend upon the final valuation of the conversion feature of our outstanding convertible promissory notes.

 

 

 

Keep reading